SOLICITATION NOTICE
B -- Vitamin D Assay on PLCO Samples
- Notice Date
- 8/1/2008
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80156-NG
- Archive Date
- 8/26/2008
- Point of Contact
- Ashley L. Virts, , Malinda L Holdcraft,, Phone: (301) 402-4509
- E-Mail Address
-
virtsa@mail.nih.gov, holdcram@exchange.nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis, an analysis of prediagnostic levels of serum vitamin D metabolites and risks of cancers of the kidney, ovary, endometrium and upper gastro-intestinal tract with Heartland Assays; 2325 N. Loop Dr., Ste. 6300; Ames, IA 50010. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 541690 the business size standard is 6.5 M employees. The period of performance for this procurement is September 1 – September 12, 2008. The objective of this procurement is an analysis for the measurement of 25-hydroxyvitamin D (25(OH)D), a measure of vitamin D status, in 1,141 serum samples from participants in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. These measurements within PLCO samples are being performed as part of a large, multi-study pooling project investigating whether serum levels of 25(OH)D are associated with subsequent risks of four types of cancer (kidney, ovary, endometrium and upper gastro-intestinal tract). Serum measurements of 25(OH)D from over 5,000 individuals from ten cohort studies will be included in the overall pooling project. Of the 5,000 samples, 1,141 samples are from the PLCO cohort study. Vitamin D is a dietary fat-soluble prohormone, which can also be generated in the skin on sunlight exposure. 25(OH)D is the primary circulating form of vitamin D and is considered the best biomarker of vitamin D status. Experimental evidence that vitamin D inhibits tumor growth and metastatic spread has generated considerable interest in the possibility that this hormone reduces cancer risk in humans. Most epidemiologic research of 25(OH)D has focused on cancers of the breast, prostate and colon. However, there is reason to suspect that other, rarer, malignancies may be sensitive to this hormone. In particular, there is evidence supporting a relationship between vitamin D and cancers of the kidney, ovary, endometrium and upper gastrointestinal tract. However, no epidemiologic studies to date have directly investigated whether 25(OH)D levels are inversely associated with risk in these rare cancers. This multi-study pooling project is being conducted to investigate this research question. Baseline serum 25(OH)D level will be measured in case and control participants. Heartland Assay has performed these services & similar services for related PLCO projects. The 25(OH)D measurements within PLCO serum samples to be covered by this procurement are being performed as part of a large multi-study pooling project, expected to include measurements from over 5,000 participants from ten different studies. For scientific comparability, it is critical that the vitamin D assays performed for all studies participating in this pooling project be carried out at the same laboratory. Heartland Assays is the only laboratory known to the NCI that can perform the assays for all of the studies in this pooling project. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on August 11, 2008. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Malinda Holdcraft: holdcram@exchange.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-80156-¬NG on all correspondence.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=6383b2e520f37e29ee4ad82234f905e1&tab=core&_cview=1)
- Record
- SN01629424-W 20080803/080801223146-6383b2e520f37e29ee4ad82234f905e1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |